Non alcocholic steatohepatitis. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group: 140 mg of Silymarin BID during 6 month. Intervention 2: Contorol group: placebo.
Treatment - Drugs
Placebo
Intervention group: 140 mg of Silymarin BID during 6 month
Contorol group: placebo
Sponsors
Mazandaran University of Medical Sciences and Health Services
Eligibility
Sex/Gender
All
Age
20 Years to 100 Years
Inclusion criteria
Inclusion criteria: Including criteria: older than 20 years with nonalcoholic- fatty liver disease and liver enzymes> 50 and proportion of ALT/ AST> 1 Excluding criteria: using drugs that affect liver tests during the last 2 months, viral hepatitis, hemochromatosis, autoimmune hepatitis, cirrhosis, diabetes mellitus, alcohol dependency, pregnancy, breast feeding, and infectious diseases
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AST. Timepoint: Before and 6 months after the therapy. Method of measurement: laboratory.;ALT. Timepoint: Before and 6 months after the therapy. Method of measurement: laboratory.;Sonographic markers. Timepoint: Before and 6 months after the therapy. Method of measurement: by Radiologist. | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight. Timepoint: Before and 6 month after the therapy. Method of measurement: balance.;BMI. Timepoint: Before and 6 months after the therapy. Method of measurement: Weight(kg)/height^2(m2).;TG. Timepoint: Before and 6 months after the therapy. Method of measurement: laboratory.;FBS. Timepoint: before and 6 months after the therapy. Method of measurement: laboratory. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Torang Taghvaei
Mazandaran Univercity of Medical Sciences and Health Services
Outcome results
None listed